Avalo Therapeutics (AVTX) Liabilities from Discontinued Operations (2018 - 2021)

Avalo Therapeutics' Liabilities from Discontinued Operations history runs 4 years deep, the most recent figure standing at 10000.0 for Q3 2021.

• Quarterly Liabilities from Discontinued Operations changed N/A year-over-year to 10000.0 in Q3 2021, while the trailing twelve-month figure through Sep 2021 was 10000.0 (changed N/A YoY) and the FY2020 annual result came in at 1341000.0, down 23.59% from the prior year.
• Liabilities from Discontinued Operations was 10000.0 for Q3 2021 at Avalo Therapeutics, down from 98000.0 in the prior quarter.
• Across five years, Liabilities from Discontinued Operations topped out at 7549631.0 in Q4 2018 and bottomed at 10000.0 in Q3 2021.
• A 4-year average of 1827105.17 and a median of 775000.0 in 2020 frame the typical range for Liabilities from Discontinued Operations.
• Annual changes were most pronounced in 2019 — Liabilities from Discontinued Operations slumped 76.75% — and 2020, when it decreased 23.59%.
• Avalo Therapeutics' Liabilities from Discontinued Operations stood at 7549631.0 in 2018, then slumped by 76.75% to 1755000.0 in 2019, then declined by 23.59% to 1341000.0 in 2020, then slumped by 99.25% to 10000.0 in 2021.
• Business Quant data shows AVTX's Liabilities from Discontinued Operations at 10000.0 in Q3 2021, 98000.0 in Q2 2021, and 209000.0 in Q1 2021.